AFMD חוב כולל להון Affimed N.V.

Affimed revenues are based on the development of tumor therapies, where licensing royalties and partner payments for access to ROCK technology generate profit. Management is currently minimizing costs and optimizing research amid a shortage of funds. This price chart reflects a market trend for the asset with a debt-to-equity ratio of 0.00, while a staff of leading scientists continues to develop innovative cancer treatment methods.

This ratio measures the degree of financial leverage by comparing total borrowings against the net value of owner assets. Analyzing the total liabilities-to-equity ratio allows for an assessment of Affimed (AFMD) resilience to default, which is critical for the biotechnology sector, where the development of the ROCK platform and the receipt of royalties from partners require strict control over the debt load.